Lophius Biosciences Announces Granting of Another Key Patent in the U.S.

Lophius Biosciences Announces Granting of Another Key Patent in the U.S.
Regensburg, Germany, November 15, 2010 / b3c newswire / - Lophius Biosciences announced today that the USTPO has granted the U.S. Patent US 78293318 entitled "Use of urea-adjuvanted polypeptides for diagnosis, prophylaxis and therapy".

 

This patent represents a key building block with respect to Lophius Biosciences T-cell based proprietary UREA technology platform, which has been used by the company already for the development of its diagnostic T-Track® Tx test. This test allows the broad and highly sensitive monitoring of cell-mediated immunity (CMI) in immunosuppressed transplant patients. A corresponding patent has been granted in the E.U already and is nationalized in major markets.

 

"Following the positive decision by the U.S patent office in early 2010 with respect to patent granting for our proprietary Reverse T-Cell technology, we are very delighted to possess broad patent protection for the UREA technology platform in the most important markets worldwide", said Dr. Michael Lutz, CEO of Lophius Biosciences.

 

„The UREA technology is a novel platform which enables parallel stimulation of a broad spectrum of clinically relevant immune cells based on its unique mechanism of action. For the 1st time, this allows the development of in vitro diagnostic products that are capable to mimic and evaluate the critical in vivo cellular immune functions. Furthermore, this technology also potentially opens up the opportunity to develop novel adjuvant-free vaccines with a strongly improved profile", added PD Dr. Deml, Chief Scientific Officer of Lophius Biosciences.

 

 

About Lophius Biosciences - www.lophius.de

Lophius Biosciences GmbH is a spin off of the Universitätsklinik Regensburg focusing on the development and marketing of innovative T-cell based test systems for the diagnosis and potential therapy guidance in the fields of transplantation, and infectious and autoimmune diseases.

 

Contact:

Marc Akteries

Tel: +49 941 6309 1972

Email: [email protected] e-mail address is being protected from spambots. You need JavaScript enabled to view it

http://www.lophius.de

 

 
 

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.